{
  "docId": "019dd923-622c-750b-8b99-daa7bab7aec2",
  "docSlug": "f687a225f056",
  "documentTitle": "Enfusion, Inc. (ENFN)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2024-03-14 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 26,
  "pageCount": 30,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "thesis_headline",
  "function": "summarize",
  "density": "sparse",
  "nDataPoints": 2,
  "notes": "This is a cover or section divider slide for a short-selling research report.",
  "elementsJson": [
    "headline_text"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-daa7bab7aec2/26",
  "deckHref": "/decks/019dd923-622c-750b-8b99-daa7bab7aec2",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-daa7bab7aec2.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-daa7bab7aec2#slide-26",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We See 40% – 60% Downside Risk To Enfusion’s Stock Price",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-78b5-7512-b5b7-386e65ff1729",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.45,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Proprietary and Confidential –May Not Be Distributed or Copied Without Spruce Point Capital Management, LLC Consent",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b8e30bf-85d7-4334-b53c-e1a1a8662c67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.07,
        "y": 0.3
      },
      "kind": "image",
      "text": "Spruce Point Capital Management logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83c92f56-e183-45cb-ae18-a7cdf97d9ab4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "downside risk: 40% – 60%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-78b5-7512-b5b7-3f8add22254a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.58,
        "x": 0.34,
        "y": 0.44
      },
      "kind": "title",
      "text": "We See 40% – 60% Downside Risk To Enfusion's Stock Price",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "102909df-45de-4c3a-96b3-484c9d4df438",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 26,
      "beatId": "3ee17b3d-3af3-45f1-b93f-4cac15396404",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Thesis Headline",
      "beatSlug": null,
      "evidence": "The document presents its main thesis of a 40% - 60% downside risk to Enfusion's stock price",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 28,
      "from": 23,
      "beatId": "5d837ca3-3b2c-4012-bccf-1779a590d5de",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Preempt Rebuttal",
      "beatSlug": null,
      "evidence": "Spruce Point preempts potential rebuttals to its analysis",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 22,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "0e49f9c0-3ee3-452c-bf97-4682f1fb7335",
      "evidence": "The document highlights the potential cost of inaction for investors who fail to act on Enfusion's concerns",
      "position": 2,
      "objective": "What is the cost of inaction for investors who fail to act on Enfusion's concerns?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}